Published online before print May 3, 2007

This Article Full Text (Rapid PDF) All Versions of this Article: ajpath.2007.060965v1 171/1/304    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, X. Articles by Chen, C. Search for Related Content PubMed Articles by Wang, X. Articles by Chen, C.

Copyright © 2007 American Society for Investigative Pathology
American Journal of Pathology, doi:10.2353/ajpath.2007.060965

Accepted for publication March 15, 2007.

Article

Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Cholesterol Efflux from Human Macrophage-Derived Foam Cells

From the Molecular Surgeon Research Center, Division of Vascular Surgery and Endovascular Therapy, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas

^@ To whom correspondence should be addressed. E-mail: jchen{at}bcm.tmc.edu.

	Abstract

Clinical use of human immunodeficiency virus protease inhibitors such as ritonavir may be associated with cardiovascular disease. The objective of this study was to determine the effects and molecular mechanisms of ritonavir on cholesterol efflux from human macrophage-derived foam cells, which is a critical factor of atherogenesis. Human THP-1 monocytes and peripheral blood mononuclear cells were preincubated with acetylated low-density lipoprotein and [³H]cholesterol to form foam cells, which were then treated with apolipoprotein A-I for cholesterol efflux assay. A clinically relevant concentration of ritonavir (15 µmol/L) significantly reduced cholesterol efflux from THP-1 and peripheral blood mononuclear cells to apolipoprotein A-I by 30 and 29%, respectively, as compared with controls. In addition, ritonavir significantly decreased the expression of scavenger receptor B1 and caveolin-1, whereas it significantly increased superoxide anion production and activated extracellular signal-regulated kinase (ERK) 1/2 in macrophages. Mitochondrial membrane potential was significantly reduced, whereas NADPH oxidase subunits were increased in ritonavir-treated macrophages. Consequently, the antioxidant seleno-L-methionine, the specific ERK1/2 inhibitor PD98059, or infection of a recombinant adenovirus encoding the dominant-negative form of ERK2 effectively blocked ritonavir-induced decrease of cholesterol efflux. Therefore, human immunodeficiency virus protease inhibitor ritonavir significantly inhibits cholesterol efflux from macrophages, which may be mediated by mitochondrial dysfunction, oxidative stress, ERK1/2 activation, and down-regulation of scavenger receptor B1 and caveolin-1.

This article has been cited by other articles:

				J. Pou, A. Rebollo, N. Roglans, R. M. Sanchez, M. Vazquez-Carrera, J. C. Laguna, J. Pedro-Botet, and M. Alegret Ritonavir Increases CD36, ABCA1 and CYP27 Expression in THP-1 Macrophages Experimental Biology and Medicine, December 1, 2008; 233(12): 1572 - 1582. [Abstract] [Full Text] [PDF]

				X. Wang, D. Liao, U. Bharadwaj, M. Li, Q. Yao, and C. Chen C-Reactive Protein Inhibits Cholesterol Efflux From Human Macrophage-Derived Foam Cells Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 519 - 526. [Abstract] [Full Text] [PDF]

				J. Laurence, R. Modarresi, X. Wang, Q. Yao, and C. Chen Modeling Metabolic Effects of the HIV Protease Inhibitor Ritonavir In Vitro Am. J. Pathol., November 1, 2007; 171(5): 1724 - 1725. [Full Text] [PDF]